Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia

Wenjun Zhang, MD, Yi Ding, MD, Hao Wu, BS, Yuhua Chen, BS, Huina Lu, MD, Chunying Chen, MD, Jianfei Fu, PhD, Weiguang Wang, PhD, Aibin Liang, PhD, and Shanhua Zou, MD

Abstract: This retrospective study compared efficacy and safety of fludarabine combined with intermediate-dose cytarabine (FA regimen) versus high-dose cytarabine (HiDAC regimen) as consolidation therapy in acute myeloid leukemia (AML) patients who achieved complete remission.

Disease-free survival (DFS) and overall survival (OS) based on age (>60, <60 years) and cytogenetics were evaluated from data between January 2005 and March 2013.

Total 82 patients (FA, n = 45; HiDAC, n = 37; 14–65 years) were evaluated. Five-year DFS was 32.0% and 36.2% for FA and HiDAC groups, respectively (P = 0.729), and 5-year OS was 39.5% and 47.8% (P = 0.568), respectively. Among older patients (>60 years), 3-year DFS was 26.0% for FA group and 12.5% for HiDAC group (P = 0.032), and 3-year OS was 34.6% and 12.5%, respectively (P = 0.026). In FA group, hematological toxicities were significantly lower. FA regimen was as effective as HiDAC regimen in patients with good/intermediate cytogenetics and significantly improved DFS and OS in older patients.

(Medicine 93(27):e134)

Abbreviations: AML = acute myeloid leukemia, ara-CTP = ara-C 5′-triphosphate, CBF = core binding factor, CNS = central nervous system, CR = complete remission, DFS = disease-free survival, FA regimen = fludarabine combined with intermediate-dose cytarabine, FAB = French–American–British, FLAG regimen = fludarabine plus intermediate-dose cytarabine, -granulocyte colony-stimulating factor [G-CSF], HiDAC regimen = high-dose cytarabine, HSCT = hematopoietic stem cell transplantation, MD-AML = multilineage dysplasia, MDS = myelodysplastic syndromes, OS = overall survival, WHO = World Health Organization.

INTRODUCTION

Chemotherapeutic agents for remission induction and consolidation in acute myeloid leukemia (AML) mostly include cytarabine in combination with other anticancer drugs (eg, anthracycline or anthracenedione). Literature suggests that early studies have established the role of high-dose cytarabine for remission induction and consolidation despite the associated toxicities, especially in the elderly population.

However, the optimal dose of cytarabine remains controversial as recent studies have challenged the role of high-dose cytarabine in both remission induction and consolidation.

Regarding consolidation therapy, a variety of modifications to chemotherapeutic regimens/combinations are available in literature, with their primary goal being maintenance of remission or increase in disease-free survival (DFS) and overall survival (OS) with minimal toxicity. One such regimen is the FLAG regimen (fludarabine + intermediate-dose cytarabine + granulocyte colony-stimulating factor [G-CSF]) used with or without modifications in various studies for the treatment of refractory or relapsed AML.

In view of the available literature on the indication and applicability of the FLAG regimen, at our institute, we use a modified FLAG (FA) regimen with intermediate-dose cytarabine or high-dose cytarabine (HiDAC) as consolidation therapy. Estey et al have shown that complete response and survival rate with FA or FLAG regimens were similar in patients with newly diagnosed AML or myelodysplastic syndromes (MDS).

Furthermore, when fludarabine is used in combination with cytarabine, it potentiates the intracellular accumulation of ara-C 5′-triphosphate (ara-CTP–active metabolite of cytarabine), thereby enabling significant dose reduction of cytarabine. This is important because at the molecular level, ara-CTP saturates the phosphorylating enzymes at plasma concentrations of >10 μmol/L, thereby raising concerns regarding the use of HiDAC.

The above-mentioned evidence suggests that the FA regimen with intermediate-dose cytarabine can serve as an alternative to HiDAC regimen to achieve the aim of consolidation therapy. Therefore, keeping in mind the importance of consolidation therapy in terms of efficacy, age of the patient, toxicity, and...
genetic heterogeneity, this retrospective study evaluated the FA regimen versus HiDAC regimen as consolidation therapy in non-M3 AML patients who achieved complete remission (CR).

MATERIALS AND METHODS

Study Design
This retrospective, observational study evaluated the outcome of non-M3 AML patients who achieved CR and were followed by consolidation chemotherapy with either FA or HiDAC regimen at the Tongji Hospital of Tongji University from January 2006 to March 2013. Patients who received a uniform induction regimen consisting of cytarabine (100 mg/m² as a continuous intravenous infusion daily for 7 days and daunorubicin 60 mg/m² intravenous push daily for 3 days) were identified. Among them, patients who achieved CR and were assigned to either FA or HiDAC regimen were evaluated. After CR, 1 or 2 cycles of additional intrathecal dexamethasone, methotrexate, and cytarabine were administered to the patients. Thereafter, patients were divided into subgroups based on their cytogenetic abnormalities, as reported in published literature. Patients with AML characterized by t(8; 21) or inv16 were considered to have favorable cytogenetics. Patients with −5, −7, del(5q), abnormal 3q, or complex cytogenetics—defined as the presence of at least 5 unrelated cytogenetic abnormalities—were considered to have adverse cytogenetics. The remaining patients were considered to have intermediate cytogenetics. Furthermore, these patients were not considered for hematopoietic stem cell transplantation (HSCT) because randomized studies comparing HSCT with high-dose cytarabine have failed to demonstrate any survival benefit in first remission. Both this study and the use of FA regimen as consolidation therapy were approved by the ethics committee of the Tongji Hospital.

Patients
Male and female patients age between 14 and 65 years with non-M3 AML who achieved CR with 1 or 2 cycles of induction chemotherapy and were subsequently treated with FA or HiDAC regimen were included. Patients with severe cardiopulmonary insufficiency were excluded.

Treatment
Consolidation therapy with the FA regimen consisted of fludarabine at a dose of 30 mg/m² followed 4 h later by cytarabine at a dose of 1000 mg/m² over 3 h daily for 3 days. Consolidation therapy with the HiDAC regimen consisted of cytarabine administered at a dose of 2000 mg/m² through 3 h intravenous infusion at 12-h intervals on days 1, 2, and 3. In addition, dexamethasone eye drops were used as prophylaxis. Best supportive care included the administration of antibiotics and red blood cells and platelet transfusions, when indicated. To minimize the risk of transfusion-associated graft-versus-host disease, patients who required blood transfusion in the FA group were transfused with irradiated blood only.

Definitions and Evaluation of Response
CR was defined as the reconstitution of normal cellular bone marrow with <5% blast cells along with a peripheral blood neutrophil count >1.0 x 10³/µL, a platelet count >100 x 10³/µL, and no evidence of extramedullary leukemia. Relapse was defined as the presence of at least one of the following: reappearance of leukemic blasts in peripheral blood, recurrence of >5% blasts in bone marrow, and appearance of extramedullary leukemia. DFS was defined as the time from achievement of CR to disease recurrence or death from any cause. OS was determined as the time interval from the date of diagnosis to the date of last follow-up or death.

Assessments
Bone marrow examination was performed to confirm CR in both groups before each consolidation therapy and at the end of all consolidation therapies. DFS and OS were evaluated among older (≥60 years) and younger (<60 years) patients and those distributed in the 3 cytogenetic subgroups. Safety assessments included adverse event profile and hematological and nonhematological toxicity, which were recorded according to the World Health Organization (WHO) criteria.

Statistical Analysis
Descriptive statistics were used to assess patient demographics, disease characteristics, and related covariates of interest. Categorical variables such as gender, French–American–British (FAB) subgroup, cytogenetics analysis, time of induction to first remission, toxic grade, and support care were summarized with counts and percentages. Continuous variables such as age at diagnosis, initial white blood cell counts, and follow-up duration were summarized as median and range, as necessary. Chi-square test was used to assess the association between the categorical variables and nonparametric test was used to compare continuous variables between the 2 regimens. DFS and OS were calculated by the Kaplan–Meier method, and the log-rank test was applied to calculate the significance of differences between survival curves. The P value for all statistical comparisons was two-tailed and differences were considered to be statistically significant when the P value was <0.05. Statistical analyses were performed using SPSS version 19.0 (SPSS Inc, Chicago, IL) and GraphPad Prism version 5.01 software for Windows (GraphPad Software, San Diego, CA).

RESULTS

Patient Characteristics
A total of 82 patients who met the inclusion criteria were identified. Of these, 45 patients (age range: 14–65 years) received the FA regimen and 37 patients (18–65 years) received the HiDAC regimen. There was a similar distribution of patients with regard to gender, age, initial white blood cells, FAB classification, cytogenetics, and courses of induction therapy to time of induction to first remission between the 2 treatment groups (P > 0.05) (Table 1). A similar patient distribution was noted between the 3 cytogenetic subgroups in the 2 treatment groups (P > 0.05) (Table 2). All patients identified were evaluated, and no dropout, loss to follow-up, or noncompliance was reported in the study.

Outcome of Consolidation
The median follow-up of all the surviving patients was 29 months (range: 9–82 months). At the 5-year follow-up, 4 patients each in the FA and HiDAC groups remained alive.

Survival curves for all patients in the FA group versus HiDAC group are shown in Figure 1. Furthermore, the 5-year DFS was 32.0% and 36.2% (P = 0.729, Figure 1A) and the 5-year OS was 39.5% and 47.8% (P = 0.568, Figure 1B) for the FA and HiDAC groups, respectively.

In patients with favorable cytogenetics, the 5-year DFS was 50.0% and 56.3% (P = 0.747) and the 5-year OS was 60.0% and...
70.0% \((P = 0.927)\) for the FA and HiDAC groups, respectively (Figure 2, which shows 5-year DFS [Figure 2A] and 5-year OS [Figure 2B]). In patients with intermediate cytogenetics, the 5-year DFS was 36.3% and 33.6% \((P = 0.973)\) and the 5-year OS was 50.5% and 50.8% \((P = 0.728)\) for the FA and HiDAC groups, respectively (Figure 3, which shows 5-year DFS [Figure 3A] and 5-year OS [Figure 3B]). In patients with adverse cytogenetics, the 2-year DFS was 8.2% and 23.1% \((P = 0.048)\) and the 2-year OS was 8.2% and 35.9% \((P = 0.043)\) for the FA and HiDAC groups, respectively (Figure 4, which shows 2-year DFS [Figure 4A] and 2-year OS [Figure 4B]).

Among older patients (≥60 years), the 3-year DFS was 26.0% and 12.5% \((P = 0.032)\) and the 3-year OS was 34.6% and 12.5% \((P = 0.026)\) for the FA and HiDAC groups, respectively (Figure 5, which shows 3-year DFS [Figure 5A] and 3-year OS [Figure 5B]). The clinical characteristics and outcomes of older patients are shown in Table 3. Among the younger patients (<60 years), the 5-year DFS was 32.0% and 42.2% \((P = 0.187)\) and the 5-year OS was 41.2% and 57.4% \((P = 0.114)\) for the FA and HiDAC groups, respectively (Figure 6, which shows 5-year DFS [Figure 6A] and 5-year OS [Figure 6B]).

Hematological Toxicity of Consolidation Therapy

A total of 168 and 137 chemotherapy courses were given to 45 and 37 patients in the FA and HiDAC treatment arms, respectively. The tolerance to FA and HiDAC regimens (including relapse and death) in terms of number and age (<60 years and ≥60 years) of patients who received 4 courses of chemotherapy is presented in Table 4.

Hematological toxicity of consolidation chemotherapy regimen is presented in Table 5. Compared with the FA group, the HiDAC group was associated with more life-threatening anemia (WHO grade 4; 21.4% versus 79.6%, \(P < 0.001\)), leukopenia (58.9% versus 86.1%, \(P < 0.001\)), neutropenia (74.4% versus 95.6%, \(P < 0.001\)), and thrombocytopenia (76.2% versus 96.4%, \(P < 0.001\)). A significantly higher frequency of severe infections was documented during severe neutropenia in the HiDAC group compared with the FA group (35.8% versus 24.4%, \(P = 0.03\)). Furthermore, the white blood cell recovery was higher than 2.0 \(\times 10^9\) L⁻¹, with a significantly shorter median time of 18.0 days (95% confidence interval [CI]: 17.9–20.4) in the FA group versus 23.0 days (95% CI: 22.6–25.0) in the HiDAC group \((P < 0.001)\). Red blood cell transfusions were required in 11.3% and 43.8% of chemotherapy courses in the FA and HiDAC groups, respectively \((P < 0.001)\). Platelet transfusions were required in 61.9% and 88.3% of chemotherapy courses in the FA and HiDAC groups, respectively \((P < 0.001)\). Overall, the FA regimen was less toxic than the HiDAC regimen.

Nonhematological Toxicity of Consolidation Therapy and Support Care

A total of 82 patients in both groups experienced grade 1 and 2 nonhematological toxicities, including nausea, vomiting, and baldness (data not shown). Fifteen patients reported liver dysfunction, which recovered after treatment with hepatoprotective agents. Twenty-six patients in the FA group received antiviral prophylaxis. Fifteen of 19 (78.9%) patients who did not receive prophylaxis had herpes zoster virus infection compared with 8 of 26 (30.8%) patients who received antivirus prophylaxis. There

| Variables | FA Group (n = 45) | HiDAC Group (n = 37) | \(P\) |
|-----------|------------------|----------------------|------|
| Gender    |                  |                      |      |
| Male      | 28               | 18                   | 0.53 |
| Female    | 17               | 19                   |      |
| Age (years, median) | 14–65 (52) | 18–65 (47) | 0.41 |
| Initial WBC (10⁹/L, median) | 0.7–484.0 (27.0) | 1.5–330.4 (30.0) | 0.26 |
| FAB subgroup |                |                      |      |
| AML-M0    | 8                | 4                    | 0.77 |
| AML-M1    | 8                | 7                    |      |
| AML-M2    | 9                | 9                    |      |
| AML-M4    | 8                | 9                    |      |
| AML-M5    | 5                | 6                    |      |
| AML-M6    | 3                | 1                    |      |
| AML-M7    | 0                | 1                    |      |
| Cytogenetics risk group |              |                      |      |
| Favorable | 9                | 8                    | 0.88 |
| Intermediate | 22              | 16                   |      |
| Adverse   | 14               | 13                   |      |
| No. of induction courses | 1 | 16 | 0.48 |
|           | 2                | 21                   |      |

AML = acute myeloid leukemia, FA = modified FLAG regimen with intermediate-dose cytarabine and fludarabine, FAB = French-American-British, HiDAC = high-dose cytarabine, WBC = white blood cells.
### TABLE 2. Baseline Characteristics of the Patients by Cytogenetics Subgroups

| Variables                  | Favorable Risk Cytogenetics | Intermediate Risk Cytogenetics | Adverse Risk Cytogenetics |
|----------------------------|-----------------------------|-------------------------------|---------------------------|
|                           | FA Group (n = 9) | HiDAC Group (n = 8) | FA Group (n = 22) | HiDAC Group (n = 16) | FA Group (n = 14) | HiDAC Group (n = 13) | P   |
| Gender                     | Male 5              | 4                             | Male 10                 | 9                        | 10               | 5                        | 0.82 |
|                           | Female 4             | 4                             | Female 12               | 7                        | 4                | 8                        | 0.09 |
| Age (years, median)        | 22–65 (55)          | 30–65 (42.5)                  | 14–65 (48.5)            | 18–63 (47.5)             | 34–65 (53)       | 29–65 (46.0)             | 0.34 |
| Initial WBC (10⁹/L, median) | 3.1–60.0 (11.7) | 6.7–115.3 (24.2)             | 1.4–143.0 (37.6)        | 1.5–330.4 (29.0)         | 0.7–484.0 (21.3) | 20.4–110.4 (34.4)        | 0.11 |
| FAB classification          | AML-M0 0            | 0                             | AML-M0 4                | 0                        | 4                | 4                        | 0.89 |
|                           | AML-M1 0             | 0                             | AML-M1 4                | 5                        | 4                | 5                        | 0.27 |
|                           | AML-M2 7             | 6                             | AML-M2 2                | 3                        | 4                | 2                        | 0.72 |
|                           | AML-M4 2             | 2                             | AML-M4 5                | 5                        | 4                | 2                        | 0.09 |
|                           | AML-M5 0             | 0                             | AML-M5 5                | 1                        | 0                | 0                        | 0.90 |
|                           | AML-M6 0             | 0                             | AML-M6 2                | 1                        | 4                | 5                        | 0.90 |
|                           | AML-M7 0             | 0                             | AML-M7 0                | 1                        | 1                | 0                        | 0.07 |
| No. of induction courses    | 1 5                  | 4                             | 1 11                    | 9                        | 11               | 7                        | 0.70 |
|                           | 2 4                  | 4                             |                          |                          |                  |                          |      |
A significant difference between those who received and did not receive antivirus prophylaxis ($P = 0.001$).

**DISCUSSION**

This retrospective study evaluated the FA regimen versus the HiDAC regimen as consolidation therapy in non-M3 AML patients who achieved CR. The FA regimen was as effective as the HiDAC regimen for consolidation in terms of DFS and OS in AML patients with good or intermediate cytogenetics but with less hematological toxicities. Furthermore, the FA regimen also significantly improved DFS and OS in older patients.

Two decades ago, the Cancer and Leukemia Group B Study (CALGB) trial demonstrated that HiDAC was superior to standard-dose cytarabine in improving DFS, making HiDAC therapy the standard consolidation regimen for patients <60 years. However, subsequently, numerous studies challenged the role of HiDAC in the consolidation of AML. The Australasian Leukemia and Lymphoma Group AML trial number 7 protocol indicated that HiDAC did confer additional benefits compared with the conventional dose of cytarabine for consolidation. The CALGB-9222 study also showed no difference in DFS and OS between the HiDAC group and the intensified sequential multiagent chemotherapy group. Similarly, the JALSG AML201 study showed that HiDAC was not superior to multiagent chemotherapy in improving the DFS and OS. The Leukemia Working Group of the Dutch–Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK) study revealed that no significant differences in event-free survival (EFS) or OS were noted between intermediate-dose cytosine arabinoside and HiDAC. Similarly, our study showed that there was no statistically significant difference in DFS or OS between the FA group and the HiDAC group. HiDAC regimen showed no extra benefits in improving the survival of AML patients compared with FA regimen.

Cytogenetics is considered one of the most valuable prognostic determinants in adult AML patients as a specific subgroup could benefit from the HiDAC regimen. Chromosomal abnormalities with favorable cytogenetics targeting the core binding factor (CBF), including t(8; 21)—morphologically associated with the FAB AML-M2—and inv16—associated with AML-M4E0—are reported to respond most effectively to the HiDAC regimen. In our study, the distribution of patients between favorable, intermediate, and adverse cytogenetics was similar to that reported in literature for a similar Chinese population with AML. Our study showed that the postremission 5-year DFS of CBF leukemia treated with HiDAC regimen was 56.3%, which is similar to that in the JALSG AML201 study (57%) and slightly more than that reported by Bloomfield et al (50%). One possible explanation for the difference is that some patients with CBF abnormality have KIT mutations, which confer higher relapse risk on CBF AML. Furthermore, a high mutation rate of c-KIT is reported among Asian patients with t(8; 21) from China and Japan. This high mutation rate of c-KIT might result in lower DFS. Unfortunately, our study did not perform the screening of
mutations in the entire coding region of \(c-KIT\) gene during the time the 2 cohorts were treated. In our study, there was no significant difference in DFS or OS between patients with \(t(8; 21)\) (FA, \(n = 7\); HiDAC, \(n = 6\)) and \(inv16\) (FA, \(n = 2\); HiDAC, \(n = 2\)) in the 2 treatment groups (Figure 2A and B). These results were consistent with those reported by Borthakur et al.\(^{34}\) Although there was no significant difference in DFS or OS for patients with intermediate cytogenetics, patients with adverse cytogenetics reported a higher 2-year DFS and OS in the HiDAC group compared with the FA group. This suggests that the HiDAC regimen was superior to the FA regimen in improving the prognosis of patients with adverse cytogenetics and may be recommended in patients without a human leukocyte antigen-matched donor.

Pharmacokinetic studies have shown that the accumulation of ara-CTP in leukemic cells at a dose of 3000 mg/m\(^2\) cytarabine is far above the saturating concentrations.\(^{65-66}\) The dose of cytarabine is clinically relevant because HiDAC is associated with life-threatening toxic effects (WHO grade 4), which are serious and appear to be cumulative. In our study, the HiDAC regimen (4 cycles of cumulative cytarabine dose 48 g/m\(^2\)) resulted in higher incidence of life-threatening hematocytopenia, longer duration of neutropenia, higher frequency of documented infections, and higher number of transfusions compared with the FA regimen (only 12 g/m\(^2\)); however, it was equally efficacious. The possible mechanism is that the active metabolite of fludarabine, F-ara-ATP, inhibits the enzyme ribonucleotide reductase and lowers intracellular deoxyribonucleoside biphosphate pools, thereby resulting in increased accumulation of intracellular ara-CTP in the FA regimen. This benefit was more evident among older patients\(^{37}\) who are unable to tolerate the severe toxic effect of HiDAC (therefore, HiDAC is only recommended for younger patients [<60 years]). In our study, out of the 8 patients age between 60 and 65 years and treated with HiDAC, 4 (50%) died of myelosuppression-induced severe infection. However, no infection-related deaths were reported among the 11 patients age between 60 and 65 years in the FA group. Moreover, the 3-year OS in the FA group was 34.6%, thus making the FA regimen a possible alternative optimized regimen for elderly AML patients. However, it should also be noted that there is no evidence from prospective studies that intermediate- or high-dose cytarabine (HiDAC, 0.5–3 g/m\(^2\)) is superior to conventional-dose consolidation chemotherapy in older patients.\(^{1,38}\)

![FIGURE 2. Probability of DFS and OS by treatment arm for the favorable cytogenetic risk group. (A) Predicted 5-year DFS was 50.0% for the FA group \((n = 9);\) solid line) and 56.3% for the HiDAC group \((n = 8);\) dotted line; \(P = 0.747\). (B) Predicted 5-year OS was 60.0% for the FA group \((n = 9);\) solid line) and 70.0% for the HiDAC group \((n = 8);\) dotted line; \(P = 0.927\). DFS = disease-free survival, FA = modified FLAG regimen with intermediate-dose cytarabine and fludarabine, HiDAC = high-dose cytarabine, OS = overall survival.](image1)

![FIGURE 3. Probability of DFS and OS by treatment arm for the intermediate cytogenetic risk group. (A) Predicted 5-year DFS was 36.3% for the FA group \((n = 22);\) solid line) and 33.6% for the HiDAC group \((n = 16);\) dotted line; \(P = 0.973\). (B) Predicted 5-year OS was 50.5% for the FA group \((n = 22);\) solid line) and 50.8% for the HiDAC group \((n = 16);\) dotted line; \(P = 0.728\). DFS = disease-free survival, FA = modified FLAG regimen with intermediate-dose cytarabine and fludarabine, HiDAC = high-dose cytarabine, OS = overall survival.](image2)
but there are studies in favor of low-intensity prolonged consolidation in elderly patients.39,40

Furthermore, van Prooijen et al41,42 showed that the intermediate-dose cytarabine could not efficiently prevent relapse of the central nervous system (CNS) leukemia because of low detectable cerebrospinal fluid concentration (0.5 μmol/L [far below 10 μmol/L, achieved by cytarabine]) of cytarabine, requiring additional administration of intrathecal methotrexate and cytarabine to eliminate the remaining blast cells in the CNS. In our study, all patients achieving CR received 1 or 2 cycles of additional intrathecal chemotherapy before consolidation therapy. We report 1 patient in the FA group with CNS relapse, not used for monitoring therapy effectiveness. However, it must be noted that the clinical utility of these assays has not been demonstrated in large prospective studies.

In conclusion, FA was an effective consolidation regimen with less hematological toxicity compared with HiDAC in AML patients with good or intermediate cytogenetic risks. This was particularly evident in patients age between 60 and 65 years, for whom the FA regimen might be an optimizing therapy. In contrast, consolidation therapy with HiDAC was more appropriate for patients with poor cytogenetic risk profile.

AML (few examples include neuroblastoma RAS viral [v-ras] oncogene homolog [NRAS], fms-related tyrosine kinase 3 [FLT3], nucleophosmin [nucleolar phosphoprotein B23, numatrin] [NPM1], the runt-related transcription factor 1 [RUNX1], v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog [KIT], CCAAT/enhancer binding protein [C/EBP], α [CEPBA], mixed-lineage leukemia [trithorax homolog, Drosophila] [MLL], and the tet oncogene family member 2 [TET2]). Further, for more refined risk stratification, the influence of comorbidity was not assessed, and flow cytometry and polymerase chain reaction-based assays were not used for monitoring therapy effectiveness. However, it must be noted that the clinical utility of these assays has not been demonstrated in large prospective studies.

FIGURE 4. Probability of DFS and OS by treatment arm for the adverse cytogenetic risk group (A) Predicted 2-year DFS was 8.2% for the FA group (n = 14; solid line) and 35.9% for the HiDAC group (n = 13; dotted line; P = 0.043). (B) Predicted 2-year OS was 8.2% for the FA group (n = 14; solid line) and 35.9% for the HiDAC group (n = 13; dotted line; P = 0.043). DFS = disease-free survival, OS = overall survival.

FIGURE 5. Probability of DFS and OS by treatment arm for older patients (A) Predicted 3-year DFS was 26.0% for the FA group (n = 11; solid line) and 12.5% for the HiDAC group (n = 8; dotted line; P = 0.032). (B) Predicted 3-year OS was 34.6% for the FA group (n = 11; solid line) and 12.5% for the HiDAC group (n = 8; dotted line; P = 0.026). DFS = disease-free survival, OS = overall survival.
FIGURE 6. Probability of DFS and OS by treatment arm for younger patients (A) Predicted 5-year DFS was 32.0% for the FA group (n = 34; solid line) and 42.2% for the HiDAC group (n = 29; dotted line; \( P = 0.187 \)). (B) Predicted 5-year OS was 41.2% for the FA group (n = 34; solid line) and 57.4% for the HiDAC group (n = 29; dotted line; \( P = 0.114 \)). DFS = disease-free survival, FA = modified FLAG regimen with intermediate-dose cytarabine and fludarabine, HiDAC = high-dose cytarabine, OS = overall survival.

TABLE 3. Characteristics and Outcomes of Older Patients

| Regimen | Gender | Age (Years) | Initial WBC (10^9/L) | FAB Subgroup | Cytogenetics | No. of Induction Courses | Status |
|---------|--------|-------------|----------------------|--------------|--------------|--------------------------|--------|
| FA      | Female | 65          | 5.0                  | AML-M4       | Intermediate | 2                        | Died of infection after 2 cycles |
| FA      | Male   | 62          | 80.1                 | AML-M1       | Intermediate | 2                        | Died of relapse after 4 cycles   |
| FA      | Male   | 65          | 3.1                  | AML-M2       | Intermediate | 2                        | Died of relapse after 4 cycles   |
| FA      | Male   | 62          | 0.8                  | AML-M0       | Adverse      | 1                        | Died of heart disease after 4 cycles |
| FA      | Male   | 63          | 7.3                  | AML-M1       | Intermediate | 1                        | Alive                             |
| FA      | Male   | 60          | 10.4                 | AML-M0       | Adverse      | 2                        | Died of relapse after 4 cycles   |
| FA      | Male   | 61          | 32.0                 | AML-M5       | Intermediate | 1                        | Died of relapse after 4 cycles   |
| FA      | Male   | 64          | 83.0                 | AML-M5       | Adverse      | 2                        | Alive                             |
| FA      | Male   | 63          | 65.0                 | AML-M5       | Intermediate | 2                        | Alive                             |
| FA      | Female | 60          | 10.0                 | AML-M2       | Intermediate | 1                        | Alive                             |
| FA      | Female | 64          | 60.0                 | AML-M5       | Intermediate | 1                        | Alive                             |
| HiDAC   | Male   | 60          | 19.9                 | AML-M2       | Favorable    | 2                        | Died of infection after 1 cycle  |
| HiDAC   | Male   | 63          | 22.5                 | AML-M5       | Adverse      | 2                        | Died of infection after 2 cycles |
| HiDAC   | Female | 65          | 24.0                 | AML-M5       | Adverse      | 2                        | Died of infection after 2 cycles |
| HiDAC   | Male   | 62          | 30.0                 | AML-M0       | Adverse      | 1                        | Died of infection after 3 cycles |
| HiDAC   | Female | 62          | 20.4                 | AML-M1       | Adverse      | 2                        | Died of relapse after 3 cycles   |
| HiDAC   | Male   | 63          | 28.0                 | AML-M4       | Intermediate | 2                        | Died of relapse after 4 cycles   |
| HiDAC   | Female | 65          | 35.0                 | AML-M5       | Adverse      | 2                        | Died of relapse after 4 cycles   |
| HiDAC   | Male   | 60          | 60.2                 | AML-M2       | Intermediate | 1                        | Alive                             |

AML = acute myeloid leukemia, FA = modified FLAG regimen with intermediate-dose cytarabine and fludarabine, FAB = French-American-British, HiDAC = high-dose cytarabine, WBC = white blood cells.

TABLE 4. Tolerance of Modified FLAG Regimen with Intermediate-Dose Cytarabine and Fludarabine, and High-Dose Cytarabine Regimen Among Patients With AML

| Group                  | FA Regimen | HiDAC Regimen |
|------------------------|------------|---------------|
|                        | N, (%) Receiving the Full 4 Courses | P          |
| All patients           | 40/45, (88.9) | 30/37, (81.1) | 0.323      |
| Relapsed               | 4/45       | 1/37          |            |
| Died (severe infection)| 1/45       | 6/37          |            |
| Patients <60 years     | 30/32, (93.8) | 27/29, (93.1) | 0.858      |
| Patients ≥60 years     | 10/11, (90.9) | 3/8, (37.5)  | 0.048      |

AML = acute myeloid leukemia, FA = modified FLAG regimen with intermediate-dose cytarabine and fludarabine, HiDAC = high-dose cytarabine.
**TABLE 5. Hematological Toxicity of Consolidation and Support Care**

|                  | FA Consolidation | HiDAC Consolidation |
|------------------|------------------|---------------------|
|                  | Course 1 | Course 2 | Course 3 | Course 4 | Total | Course 1 | Course 2 | Course 3 | Course 4 | Total | P     |
| No. of cycles    | 45      | 43      | 40      | 40      | 168    | 37      | 36      | 34      | 30      | 137    | NA    |
| Anemia (cycles, %) | 3      | 5      | 7      | 21      | 36 (21.4%) | 23      | 30      | 30      | 26      | 109 (79.6%) | <0.001 |
| Leukopenia (cycles, %) | 17     | 23     | 26     | 33     | 99 (58.9%) | 27      | 31      | 32     | 28      | 118 (86.1%) | <0.001 |
| Neutropenia (cycles, %) | 19     | 32     | 36     | 38     | 125 (74.4%) | 34      | 35      | 32     | 30      | 131 (95.6%) | <0.001 |
| Thrombocytopenia (cycles, %) | 23     | 32     | 34     | 39     | 128 (76.2%) | 34      | 35      | 33     | 30      | 132 (96.4%) | <0.001 |
| Severe infection (cycles, %) | 6      | 9      | 12     | 14     | 41 (24.4%) | 12      | 12      | 13     | 12      | 49 (35.8%) | 0.03   |
| Treatment courses requiring RBC transfusions | 2      | 3      | 3      | 11     | 19 (11.3%) | 12      | 15      | 18     | 15      | 60 (43.8%) | <0.001 |
| Treatment courses requiring platelet transfusions | 19     | 25     | 31     | 29     | 104 (61.9%) | 30      | 33      | 31     | 27      | 121 (88.3%) | <0.001 |

FA = modified FLAG regimen with intermediate-dose cytarabine and fludarabine, HiDAC = high-dose cytarabine, NA = not applicable, RBC = red blood cell.

**REFERENCES**

1. Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program*. 2011;2011:43–50.
2. Lowenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. *Blood*. 2013;121:26–28.
3. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. *Cancer and Leukemia Group B*. *N Engl J Med*. 1994;331:896–903.
4. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. *Blood*. 1996;88:2841–2851.
5. Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. *Blood*. 2011;117:2366–2372.
6. Schaich M, Rollig C, Souchek S, et al. Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. *J Clin Oncol*. 2011;29:2696–2702.
7. Faderl S, Ravandi F, Huang X, et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with daunorubicin in acute myeloid leukemia frontline therapy for older patients. *Cancer*. 2012;118:4471–4477.
8. Hengeveld M, Suciu S, Karrasch M, et al. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulato (GIMEMA) Leukemia Cooperative Groups. *Ann Hematol*. 2012;91:825–835.
9. Lowenberg B, Suciu S, Archimbau E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. *J Clin Oncol*. 1998;16:872–881.
10. Ferrara F, Melillo L, Montillo M, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. *Ann Hematol*. 1999;78:380–384.
11. Fonf CY, Grigoradis G, Hocking J, et al. Fludarabine, cytarabine, granulocyte-colony stimulating factor and ansamycin: an effective salvage therapy option for acute myeloid leukemia at first relapse. *Leuk Lymphoma*. 2013;54:336–341.
12. Huhmann IM, Watzeke HH, Geissler K, et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. *Ann Hematol*. 1996;73:265–271.
13. Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. *Br J Haematol*. 2001;112:127–137.
14. Luo S, Cai F, Jiang L, et al. Clinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemia. *Exp Ther Med*. 2013;5:982–986.
15. Shen ZX. [FLAG regimen in the treatment of refractory and relapsed acute myeloid leukemia.]. Zhonghua Xue Ye Xue Za Zhi; 32:1–2.
16. Yang LJ, Meng FY, Xu B, et al. [Modified FLAG regimen in the management of refractory acute myeloid leukemia.]. *Di Yi Jun Yi Da Xue Xue Bao*. 2003;23:1054–1055.
17. Ferrara F, Palmieri S, Pocabi B, et al. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). *Eur J Haematol*. 2002;68:203–209.
18. Li Q, Hong M, Qian SX, et al. [Effect of FLAG consolidation therapy on mobilization of autologous peripheral blood stem cells in patients with acute myelogenous leukemia.]. Zhongguo Shi Yan Xue Za Zhi 2009;17:1335–1338.
19. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with...
fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12:671–678.
20. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116–124.
21. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–4336.
22. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–4083.
23. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649–1656.
24. Harousseau JL, Cahn YJ, Pignon B, et al. Autologous bone marrow transplantation versus intensive consolidative chemotherapy as post remission therapy in adult acute myeloblastic leukemia: final analysis of the GOELAM randomized study. Proc Am Soc Clin Oncol. 1996;15:358.
25. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;337:217–223.
26. World Health Organization. Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva. 1979. Printed in Switzerland, 79/4514-DOC-4000.
27. Bradstock KF, Matthews JP, Lowenthal RM, et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood. 2005;105:481–488.
28. Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005;105:3420–3427.
29. Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364:1027–1036.
30. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173–4179.
31. Liu H, Chang NB, Pei L, et al. [The cytogenetic characteristics of 178 acute myeloid leukemia patients.], Zhonghua Nei Ke Za Zhi. 2011;50:683–686.
32. Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/overexpression in (8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevac. Proc Natl Acad Sci U S A. 2005;102:1104–1109.
33. Nanni T, Matsuno N, Wakakita T, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring (t(8;21)(q22;q22). Leukemia. 2005;19:1361–1366.
34. Borthakur G, Kantarjian H, Wang X, et al. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008;113:3181–3185.
35. Early AP, Preisler HD, Slocum H, et al. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res. 1982;42:1587–1594.
36. Harris AL, Grahame-Smith DG. Variation in sensitivity of DNA synthesis to ara-C in acute myeloid leukemia. Br J Haematol. 1980;45:371–379.
37. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood. 2004;103:2908–2913.
38. Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98:548–553.
39. Gardin C, Turlure P, Fagot T, et al. Does the metabolite uracil arabinoside inhibit cytosine arabinoside (Ara-C) penetration into the cerebrospinal fluid during high-dose Ara-C therapy? Blood. 2001;98:548–553.
40. Nanri T, Matsuno N, Wakakita T, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring (t(8;21)(q22;q22). Leukemia. 2005;19:1361–1366.
41. van Prooijen HC, Muus P, Roelofs JM, et al. Does the metabolite uracil arabinoside inhibit cytosine arabinoside (Ara-C) penetration into the cerebrospinal fluid during high-dose Ara-C therapy? Blood. 2007;109:5129–5135.
42. Izzykson R, Gardin C, Pautas C, et al. Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica. 2011;96:837–844.
43. van Prooijen HC, Muus P, Roelofs JM, et al. Does the metabolite uracil arabinoside inhibit cytosine arabinoside (Ara-C) penetration into the cerebrospinal fluid during high-dose Ara-C therapy? Scand J Haematol. 1986;36:123–126.
44. van Prooijen HC, Punt K, Muus P. Cerebrospinal fluid concentrations of cytosine arabinoside during intravenous therapy with intermediate dose: a preliminary report. Br J Haematol. 1985;59:188–199.
45. Byrd JC, McGrail LH, Hospenthal DR, et al. Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Br J Haematol. 1999;105:445–447.